Roche deal fails to Repare the licensing scene
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Back to business for biotech flotations
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.